Lars D. Engstrom

4.3k citations

22 papers · 434 indexed · h-index 9

Oncology
- Colorectal Cancer Treatments and Studies 3
- Cancer Immunotherapy and Biomarkers 3
Hepatology
Molecular Biology
- Cancer-related gene regulation 8
- Ubiquitin and proteasome pathways 3
- Biochemical and Molecular Research 2
- PI3K/AKT/mTOR signaling in cancer 2
Immunology
Cancer Research
Pulmonary and Respiratory Medicine
- Ferroptosis and cancer prognosis 3
Computational Theory and Mathematics
- Computational Drug Discovery Methods 2

Co-authors: James G. Christensen Ruth Aranda Peter Olson David M. Briere Jill Hallin Niranjan Sudhakar Daniel S. Wechsler David Woods
Cited by: Oncology Hepatology Molecular Biology
Journals: Cancer Research (10 papers)Molecular Cancer Therapeutics (6 papers)Molecular Cancer Research (1 paper)
Partner nations: United States

In The Last Decade

Lars D. Engstrom

19 papers receiving 429 citations

Peers

Countries citing papers authored by Lars D. Engstrom

Since Specialization

Citations

This map shows the geographic impact of Lars D. Engstrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars D. Engstrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars D. Engstrom more than expected).

Fields of papers citing papers by Lars D. Engstrom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars D. Engstrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars D. Engstrom. The network helps show where Lars D. Engstrom may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Lars D. Engstrom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lars D. Engstrom Line = papers co-authored together Lars D. Engstrom links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC Cancer Research ·Marcelo V. Negrão,David Molkentine,克子猪又,Laura D. Hover,Monique B. Nilsson,Natalie I. Vokes,Lars D. Engstrom,Andrew Calinisan,Laura Waters,David M. Briere,Jill Hallin,George R. Blumenschein,Ferdinandos Skoulidis,Scott Kopetz,David S. Hong,Don L. Gibbons,Peter Olson,James G. Christensen,John V. Heymach	2024	0
2	Abstract B009: TEAD inhibition overcomes YAP1/TAZ-driven resistance to RAS inhibitors in KRASG12C-mutant cancers Molecular Cancer Research ·A. Cole Edwards,Clint A. Stalnecker,Glenda Jones,沈亮亮,Jill Hallin,慎司野沢,Mauricio Aspé-Sánchez,Lars D. Engstrom,Luiza De Sousa Ferreira de Mendonca,James G. Christensen,Adrienne D. Cox,Channing J. Der	2023	0
3	Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC Cancer Research ·達雄篠原,Niranjan Sudhakar,Jade Laguer,David M. Briere,J. Romeu,Diego Alonso Asensio,Andrew Calinisan,Lars D. Engstrom,瑛川安藤,Peter Olson,James G. Christensen,Jacob R. Haling	2023	0
4	Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers Cancer Research ·Laura Waters,Ruth Aranda,Krystal Moya,Vickie Bowcut,С. Г. Кошель,Diego Alonso Asensio,Г. С. Моисеев,Laura D. Hover,Julio Fernandez-Banet,Jill Hallin,David M. Briere,James G. Christensen,慎司野沢,Lars D. Engstrom	2023	1
5	Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers Cancer Research ·Carol Chen-Scarabelli Albert,Ruth Aranda,Laura Waters,Krystal Moya,Diego Alonso Asensio,Christopher Smith,Jill Hallin,繁誠川喜多,Lars D. Engstrom,Darin Vanderpool,廖晓军,James G. Christensen,慎司野沢	2023	1
6	Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors Bioorganic & Medicinal Chemistry ·Christopher R. Smith,Ruth Aranda,James G. Christensen,Lars D. Engstrom,Robin J. Gunn,Anthony Ivetac,John M. Ketcham,Mike Hajimichael,J. David Lawson,Matthew A. Marx,Peter Olson,Nicole C. Thomas,Xiaolun Wang,Laura Waters,Svitlana Kulyk	2022	8
7	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy Molecular Cancer Therapeutics ·David M. Briere,Shuai Li,Andrew Calinisan,Niranjan Sudhakar,Ruth Aranda,Lauren Hargis,David H. Peng,Jiehui Deng,Lars D. Engstrom,Jill Hallin,Sole Gatto,Julio Fernandez-Banet,Adam Pavlı́c̀ek,Kwok‐Kin Wong,James G. Christensen,Peter Olson	2021	109
8	Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors Cancer Research ·Christopher R. Smith,Svitlana Kulyk,A. Abd Ellatef,Lars D. Engstrom,Ruth Aranda,David M. Briere,Robin J. Gunn,Krystal Moya,Lisa Rahbæk,Laura Waters,Anthony Ivetac,James G. Christensen,Peter Olson,Matthew A. Marx	2021	10
9	Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models Molecular Cancer Therapeutics ·Christopher R. Smith,Lars D. Engstrom,Svitlana Kulyk,Ruth Aranda,Laura Waters,Krystal Moya,Vickie Bowcut,Diego Alonso Asensio,С. Г. Кошель,David M. Briere,J. David Lawson,Bijay Chauhan,Lisa Rahbæk,James G. Christensen,Matthew A. Marx,Peter Olson	2021	2
10	Abstract LBA005: Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors Molecular Cancer Therapeutics ·Ryan J. Hansen,Steven V. Horton,Kisha Hampton,Andrew Brodie,E. Lorena Mora‐Blanco,Nam Nguyen,Lars D. Engstrom,David M. Briere,Heli Altonen,Peter Olson,Mark M. Awad,Andrew J. Aguirre,Jason Christiansen,Christian A. Hassig,Shailaja Kasibhatla	2021	1
11	Abstract 5684: Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models Cancer Research ·Lars D. Engstrom,Laura Waters,Sole Gatto,Julio Fernandez-Banet,Ruth Aranda,Adam Pavlı́c̀ek,James G. Christensen,Peter Olson	2020	1
12	Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models Cancer Research ·Jill Hallin,Andrew Calinisan,Lauren Hargis,Ruth Aranda,Lars D. Engstrom,David M. Briere,Matthew A. Marx,Peter Olson,James G. Christensen	2020	1
13	Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model Molecular Cancer Therapeutics ·David M. Briere,Andrew Calinisan,Ruth Aranda,Niranjan Sudhakar,Lauren Hargis,Sole Gatto,Julio Fernandez-Banet,Adam Pavlı́c̀ek,Lars D. Engstrom,Jill Hallin,James G. Christensen,Peter Olson	2019	10
14	Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers Molecular Cancer Therapeutics ·James G. Christensen,Jay B. Fell,Jill Hallin,Brian R. Baer,Lars D. Engstrom,James F. Blake,David M. Briere,Josh Ballard,Bed Prasad Pantha,John P. Fischer,Guy Vigers,Ruth Aranda,Vickie Bowcut,Andrew Calinisan,Lauren Hargis,Niranjan Sudhakar,Matthew A. Marx,Peter Olson	2019	5
15	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy Cancer Immunology Immunotherapy ·David M. Briere,Niranjan Sudhakar,David Woods,Jill Hallin,Lars D. Engstrom,Ruth Aranda,Harrah Chiang,Andressa L. Sodré,Peter Olson,Jeffrey S. Weber,James G. Christensen	2017	117
16	Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor Molecular Cancer Therapeutics ·Helen Y. Zou,Qiuhua Li,Joseph H. Lee,Maria E. Arango,T Iziana M Eschi,Ming Qiu,Lars D. Engstrom,Shinji Yamazaki,Hassan Shehata Hassan,Sergei Timofeevski,Jingrong Jean Cui,Michele McTigue,Gerrit Los,Steven L. Bender,Tod Smeal,James G. Christensen	2012	57
17	Abstract 4504: PF-04449913, a small molecule inhibitor of Hedgehog signaling, is effective in inhibiting tumor growth in preclinical models Cancer Research ·Amy Jackson-Fisher,Melissa McMahon,Justine L. Lam,Chunze Li,Lars D. Engstrom,Konstantinos Tsaparikos,David J. Shields,Douglas D. Fang,Maruja E. Lira,Zhou Zhu,Michael Robbins,Richard B. Schwab,Michael J. Munchhof,Todd VanArsdale	2011	8
18	MXI1-0, an Alternatively Transcribed Mxi1 Isoform, Is Overexpressed in Glioblastomas Neoplasia ·Lars D. Engstrom,Andrew Youkilis,D. Higgs,Datong Zheng,V Pachev,Sebastian Sonntag,Y. Takizawa,Katherine C. Aquino,Xiaoxiang Zhu,Samir Hanash,Daniel S. Wechsler	2004	18
19	A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein Genes Chromosomes and Cancer ·Daniel S. Wechsler,Lars D. Engstrom,Brian M. Alexander,David G. Motto,Diane Roulston	2002	33
20	Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells The Prostate ·Mary Taj,I. Mircea,Lars D. Engstrom,Zhi Zeng,Clara Hwang,Martin G. Sanda,Daniel S. Wechsler	2001	43

About Lars D. Engstrom

Lars D. Engstrom is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 434 indexed citations. Recurring topics across this work include Cancer-related gene regulation (8 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Ferroptosis and cancer prognosis (3 papers), Ubiquitin and proteasome pathways (3 papers), Computational Drug Discovery Methods (2 papers), Biochemical and Molecular Research (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Oncology (204 citations), Hepatology (33 citations) and Molecular Biology (281 citations). Lars D. Engstrom has collaborated with scholars based in United States. Frequent co-authors include James G. Christensen, Ruth Aranda, Peter Olson, David M. Briere, Jill Hallin, Niranjan Sudhakar, Daniel S. Wechsler, David Woods, Andressa L. Sodré and Jeffrey S. Weber. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Molecular Cancer Research, Neoplasia and The Prostate.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact